Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More, volume II

40.5K

views

134

authors

21

articles

Editorial

10 February 2025

Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II

Zhi-Bin Wang

,

De-Hua Liao

,

Guang Lei

,

Zhao-Qian Liu

, 1 more and

Jing Wang

665 views

0 citations

Editors

5

Jing Wang

Hunan Cancer Hospital, Xiangya School of Medicine, Central South University

GUANG LEI

University of Texas MD Anderson Cancer Center

Zhi-Bin Wang

Hunan Cancer Hospital, Xiangya School of Medicine, Central South University

Zhaoqian Liu

Xiangya Hospital, Central South University

Nayiyuan Wu

Hunan Cancer Hospital, Xiangya School of Medicine, Central South University

Impact

Fetching...

About

This Research Topic is part of a series with:
Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More

Ovarian cancer is the malignancy with the highest rate of death from tumors of the female reproductive system and the main treatment options are tumor reduction and post-surgical platinum-based chemotherapy. Unfortunately, some patients will develop platinum resistance after multiple recurrences. Given that ovarian cancer is a heterogeneous disease with complex molecular and genetic alterations, the identification of specific molecular targets will be of great benefit in gaining a deeper understanding of the mechanisms of ovarian cancer development and progression.

As research into targeted therapies continues, the treatment of ovarian cancer is gradually shifting from conventional chemotherapy to targeted therapies. Targeted drugs such as PARP inhibitors and anti-angiogenic drugs have become important modalities for the maintenance treatment of ovarian cancer. At the same time, targeted therapy also suffers from ineffective use, high rates of adverse reactions and high prices. With the development of next-generation sequencing technology, targeted therapeutic agents developed for specific molecules in ovarian cancer may provide a wider range of treatment options for ovarian cancer patients and offer new strategies for individualized treatment. Immunotherapy, as well as ferroptosis pathway modulation, has also provided new ideas for targeted therapy in ovarian cancer.

How to increase the efficacy and reduce the side effects of existing targeted drugs for ovarian cancer, as well as exploring the possibility of developing new targeted drugs, are issues that are urgently before us today. We’re eager to identify new targeted treatments for ovarian cancer and investigate biomarkers associated with ovarian cancer-targeted medication. We encourage computational or experimental research as well as pharmacological activity studies.

In the first volume of this Research Topic, we provide insights into the development of targeted therapies for ovarian cancer and offer solid evidence to improve their efficacy and reduce toxicity. We have published a total of 13 latest research findings on targeted therapy for ovarian cancer, which have received positive reviews and extensive attention within the field. We have systematically reviewed and summarized these studies from two aspects: "Methods for predicting targeted therapy efficacy" and "Methods for enhancing targeted therapy efficacy" (see details at https://www.frontiersin.org/articles/10.3389/fphar.2023.1222209/full). Due to the histological characteristics of the ovarian tissue microenvironment and its nature as a “cold tumor,” research on targeted therapies for ovarian cancer, represented by immunotherapy, still faces challenges. However, despite the long road ahead, progress will ultimately be made.

In this research topic (volume II), we welcome researchers to submit perspectives, original articles, reviews, comments, and letters on the topic. Including but not limited to the following topics:

• Targeting ovarian cancer by novel molecules.
• Influence of novel ovarian cancer therapeutics on targeted medication.
• Big data analysis of ovarian cancer networks involved in metabolic, and inflammatory pathways.
• Clinical translation strategies for ovarian cancer targeted therapeutics.
• Non-coding RNA and targeted therapy for ovarian cancer.
• Anti-angiogenic drugs and ovarian cancer-targeted medication.
• PARP inhibitors and ovarian cancer-targeted medication.
• Immunotherapy and targeted ovarian cancer treatment.
• Mechanisms of drug resistance and targeted therapeutic strategies in ovarian cancer.
• Ferroptosis and ovarian cancer targeted medication.

Download ebook

PDF

EPUB

Share

Editors

Jing Wang

Hunan Cancer Hospital, Xiangya School of Medicine, Central South University

GUANG LEI

University of Texas MD Anderson Cancer Center

Zhi-Bin Wang

Hunan Cancer Hospital, Xiangya School of Medicine, Central South University

Zhaoqian Liu

Xiangya Hospital, Central South University

Nayiyuan Wu

Hunan Cancer Hospital, Xiangya School of Medicine, Central South University

Coordinators

Zhi-Bin Wang

Impact

40,507 Total views

25,864 Article views

12,578 Article downloads

2,065 Topic views

Published In

Frontiers in Pharmacology

Experimental Pharmacology and Drug Discovery, Pharmacology of Anti-Cancer Drugs

Frontiers in Oncology

Pharmacology of Anti-Cancer Drugs

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic